Protean Pathology Services

• 1978-1983 / MD, University of Naples, First Faculty, Naples, Italy 

• 1987-1988 / Resident, General Surgery, Monmouth Medical Center, Long Branch, MJ 

• 1988-1992 / Resident, Combined Anatomic and Clinical Pathology, Temple University Hospital, Philadelphia, PA 

• 1992-1994  / Fellow in Molecular Pathology, Jefferson Cancer Institute, Thomas  Jefferson University, Philadelphia, PA 

• 1994-1995  / Fellow, Surgical Pathology, University of Pittsburgh Medical Center,     Pittsburgh, PA 

• 1983, Italy, Active

• 2005, Indiana, Inactive #01059993A

• 2006, Florida, Active ME- 00691552006

• 1987 – 1988 / General Surgery, Monmouth Medical Center, Long Branch, NJ 

• 1988 – 1992 / Combined Anatomic and Clinical Pathology, Temple University Hospital, Philadelphia, PA 

• 1995 – 2003 / Member in Residence H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 

• 2003 – 2005 / Medical Director, Physicians Right Path and CytoCor Laboratories 

• 1995 – 2003 / Member of the Gastrointestinal Tumor Program, Moffitt Cancer Center and Research Institute, Tampa, FL 

• 2003 – 2005 / Clinical Associate Professor of Pathology, Department of Pathology, University of South Florida, College of Medicine, Tampa, FL 

• 2005 – 2019 / Member in Residence H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 

• 2005 – 2006 / Interim Chief Anatomic Pathology Division, Department of Interdisciplinary Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL 

• 2006 – 2008 / Chief Anatomic Pathology Division, Scientific Director Tissue Core, Scientific Co-Director Analytic Microscopy Core, Department of Interdisciplinary Oncology, Moffitt Cancer Center and Research Institute, and University of South Florida, College of Medicine, Tampa, FL 

• 2008 – 2011 / Chair Anatomic Pathology Department, Scientific Director Tissue Core and Scientific Co-Director Analytic Microscopy Core Department of Oncologic Sciences, Moffitt Cancer Center, Tampa, FL 

• 2011 – 2019 / Senior Member, Anatomic Pathology Department and Gastrointestinal Tumor Program, Moffitt Cancer Center and Research Institute, Tampa, FL 

• 2019 – 2024 /  Director Pathology Laboratory, Florida Digestive Health Specialists, Lakewood Ranch, Florida 

• 2024 – Present / Independent Contractor, DPCO Consulting, LLC 

1. My publications have mostly focused on markers of tumor progression. This effort included especially studies on the role of IGF1R in tumor proliferation, invasion, metastasis and  apoptosis in colorectal and ovarian cancers; and the studies of the immunogenic phenotype in colon cancer. 

a. Himbert C, Figueiredo JC, Shibata D, Ose J, Lin T, Huang LC, Peoples AR, Scaife CL, Pickron B, Lambert L, Cohan JN, Bronner M, Felder S, Sanchez J, Dessureault S, Coppola D et al. Clinical Characteristics and Outcomes of Colorectal Cancer in the ColoCare Study. Differences by Age of Onset. Cancers (Basel). 2021 Jul 29;13(15):3817. doi:10.3390/cancers13153817. PMID: 34359718; PMCID: PMC8345133. 

b. Saller J, Qin D, Felder S, Coppola D. Microsatellite Stable Colorectal Cancer With an Immunogenic Phenotype: Challenges in Diagnosis and Treatment. Clin Colorectal Cancer. 2020 Jun;19(2):123-131. doi: 10.1016/j.clcc.2020.02.003. Epub 2020 Feb 11. PMID: 32171644. 

c. Shahid M, Wang D, Saller J, Ryzhova E, Qin D, Magliocco A, Coppola D. STK11 p.G270W: A Novel Mutation Detected in a Case of MSI High Mixed Medullary-Mucinous Carcinoma of the Transverse Colon. Cancer Genomics Proteomics. 2019 Jul-Aug;16(4):267-272. doi: 10.21873/cgp.20131. PMID: 31243107 

d. Cives M, Strosberg J, Al Diffalha S, Coppola D. Analysis of the immune landscape of small bowel neuroendocrine tumors. Endocr Relat Cancer. 2019 Jan 1;26(1):119-130. doi: 10.1530/ERC-18-0189. PMID: 30400003 

2. I have contributed to the identification of microRNAs and LincRNAs predictors of prognosis and therapy response for a variety of tumor types including breast, colon, ovarian and others. 

a. Chen DT, Hernandez JM, Shibata D, McCarthy SM, Humphries LA, Clark W, Elahi A, Gruidl M, Coppola D, Yeatman T. Complementary Strand MicroRNAs Mediate Acquisition of Metastatic Potential in Colonic Adenocarcinoma. J Gastrointest Surg. 2012: 16(5): 905-12. PMID: 22362069 

b. Donatelli SS, Zhou JM, Gilvary DL, Eksioglu EA, Chen X, Cress WD, Haura EB,Schabath MB, Coppola D, Wei S, Djeu JY. TGF-β-inducible microRNA-183 silences tumor-associated natural killer cells. Proc Natl Acad Sci U S A. 2014 Feb 28. PMCID: PMC3964044 

c. Richards EJ, Zhang G, Li ZP, Permuth-Wey J, Challa S, Li Y, Kong W, Dan S, Bui M, Coppola D (CBMM), Mao WM, Sellers TA, Cheng JQ. Long Non-coding RNAs (LncRNA) Regulated by Transforming Growth Factor (TGF) β: LncRNA-Hit-Mediated Tgfβ- Induced Epithelial to Mesenchymal Transition in Mammary Epithelia. J Biol Chem 2015 Mar; 290: (11) 6857-6867 PMCID: PMC4358111 

3. I described the presence and prognostic role of lymph node-like structures in colon cancer. This finding included the discovery of a chemokine signature capable of predicting tumor prognosis and therapy response not only in colon but also in melanoma and pancreatic cancer, as later demonstrated by other authors. 

a. Coppola D, Mule JJ. Ectopic lymph nodes within human solid tumors. J Clin Oncol. 2008 Sep 20;26(27):4369-70. PMID: 18802146. 

b. Coppola D, Nebrozhyn M, Khalil F, Dai H, Yeatman T, Loboda A, Mule JJ. Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am J Pathol. 2011 Jul;179(1):37-45, PMCID: PMC3123872 

• Medical School: University of Alberta, Edmonton, Canada 1987

• FCAP Fellow, Pathology, College of American Pathologists, 1992

• FCRPC Fellow, Anatomical Pathology, Royal College of Physicians and Surgeons of Canada, 1991

• Postdoctoral Research Fellow, Molecular Surgical Pathology, Fox Chase Cancer Centre, United States

Medical License, State of Florida

Medical License, Province of Saskatchewan

Medical License, Commonwealth of Pennsylvania

Medical License, Province of Alberta, # 010389

Qualifying Examination, Royal College of Physicians and Surgeons of Canada

Licentiate, Medical Council of Canada, # 7980

Specialty Board Examination, United States Specialty Board Examination, 1992

National Board Examination, 1988

Moffitt Cancer Center:

• Medical Director, CLIA Digital Pathology Imaging Laboratory, Moffitt Cancer Center, 2014 - 2019

• Director, Moffitt Morsani Molecular Diagnostic Laboratory, Moffitt Cancer Center, 2015 - 2019

• Scientific Director, Moffitt Tissue Core, Moffitt Cancer Center, 2015 - 2019

• Program Director, Oncology Molecular Pathology Fellowship Program, Moffitt Cancer Center, 2014 - 2019

• Medical Director, CLIA test development laboratory, Moffitt Cancer Center, 2013 - 2019

• Department Chair, Anatomic Pathology, Moffitt Cancer Center, 2011 - 2018

Medical and Scientific Director, CBCF (Canadian Breast Cancer Foundation) /ACRI (Alberta Cancer Research Institute) Biorepository, Calgary, Alberta, Canada

Division Head, Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada, 2004-2011

Director, Translational Laboratory, Tom Baker Cancer Centre, Calgary, Alberta, Canada, 2004-2011

Dr. Magliocco has published over 200 research articles, has numerous patents issued and applied, and is a frequent invited speaker to international diagnostic technology meetings.

In his extensive peer-reviewed research he has developed new digital image analysis methods and has created numerous new diagnostic tests used to aid selection of treatment plans for patients with breast, ovary, lung, bladder and many other cancers.

• Medical school: Westfälisch Wilhelms Universität in Münster, Germany, Dr med/ MD, 1987

• FRCPC Fellow: Anatomical Pathology, Royal College of Physicians and Surgeons of Canada, 1994

• Diplomat of American Board of Pathology, 1995

• Clinical Quality Improvement Program, 2017

• Medical License: Province of Saskatchewan (license number 8234)

• Medical License: Province of British Columbia

• Licentiate: Medical Council of Canada Registration (No. 73376)

• Qualifying Examination: Royal College of Physicians and Surgeons of Canada Certification in Anatomical Pathology, 1994

• Speciality Board Examination: American Board of Pathology, 1995

• Saskatoon District Medical Association (SDMA), 1996 – 2000, 2011-present

• Saskatchewan Medical Association (SMA), 1996 – present

• Canadian Medical Association (CMA), 1996 – present

• Royal College of Physicians and Surgeons of Canada (RCPSC), 1994 – present

• College of Physicians and Surgeons of Saskatchewan, 1995 – present

• College of Physicians and Surgeons of British Columbia, 1995 – 1997, April 2007

• Canadian Association of Pathologists (CAP), 1991 – present

• Saskatchewan Association of Laboratory Medicine (SALM; formerly SAP), 1991-present

• American Society of Clinical Pathologists (ASCP), 1994 – present

• College of American Pathologists (CAP), 1996 – 2024

• United States and Canadian Academy of Pathology, Inc. (UIP), 1996 – 2024

• Pacific Northwest Society of Pathologists (PNSP), 1994 – 2007

• International Society of Breast Pathology, 1999- present

Dr. Rees has co-authored multiple articles focused on various topics in breast pathology, including biomarker evaluation as well as workload in Anatomical Pathology. Other interests include quality assurance in breast pathology as well as a variety of planetary and global health topics and wellness.

• Medical School: University of Minnesota, Minneapolis, MN 2012

• Anatomic and Clinical Pathology Residency: Tulane University, New Orleans, LA 2016

• Hematopathology Fellowship: Tulane University, New Orleans, LA 2017

• Molecular Oncology Fellowship: Moffitt Cancer Center, Tampa, FL 2018

• Medical Licenses: Florida - #ME132844; Louisiana - #300971

• USMLE Step 1: 2010, passed

• USMLE Step 2: 2012, passed

• USMLE Step 3: 2013, passed

• AP/CP Board Certification: 2016

• Hematopathology Board Certification: 2018

• College of American Pathology - fellow member

• Association of Clinical Pathologist - member

Interest in molecular oncology, immunotherapy, targeted therapies, and novel immunodiagnostic testing.